BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2025 10:39:41 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-08-25 12:43 |
|
Peer-Review Started |
|
2025-08-25 12:43 |
|
First Decision by Editorial Office Director |
|
2025-09-17 08:50 |
|
Return for Revision |
|
2025-09-17 08:50 |
|
Revised |
|
2025-09-27 19:22 |
|
Publication Fee Transferred |
|
2025-10-10 11:42 |
|
Second Decision by Editor |
|
2025-11-04 02:33 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-04 08:20 |
|
Articles in Press |
|
2025-11-04 08:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-09 07:32 |
|
Publish the Manuscript Online |
|
2025-12-19 10:39 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Dual biologic therapy in patient with refractory ulcerative colitis and comorbidities: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Andreia C Guimarães, Rocio Ferreiro-Iglesias, Cristina Calviño-Suarez, Iria Baston-Rey and Manuel Barreiro-de Acosta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andreia C Guimarães, MD, Department of Gastroenterology, Unidade Local de Saude de Braga, Sete Fontes, Sao Victor, Braga 4710-243, Portugal. andreiaguimaraes32@gmail.com |
| Key Words |
Inflammatory bowel disease; Refractory ulcerative colitis; Combination therapy; Mirikizumab; Vedolizumab; Case report |
| Core Tip |
Dual biologic therapy (DBT) is a promising treatment option for patients with refractory ulcerative colitis (UC) who have limited therapeutic alternatives. We presented the first case of a patient with extensive UC treated with mirikizumab and vedolizumab due to contraindications to tumor necrosis factor and Janus kinase inhibitors. The combination of mirikizumab and vedolizumab led to sustained clinical and biochemical remission without adverse events. Our case highlighted the therapeutic potential and safety of DBT in selected patients, reinforcing the need for individualized treatment strategies in complex clinical scenarios. |
| Publish Date |
2025-12-19 10:39 |
| Citation |
Guimarães AC, Ferreiro-Iglesias R, Calviño-Suarez C, Baston-Rey I, Barreiro-de Acosta M. Dual biologic therapy in patient with refractory ulcerative colitis and comorbidities: A case report. World J Gastroenterol 2025; 31(47): 113381 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i47/113381.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i47.113381 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
